Cost-Effectiveness Analysis of Trastuzumab-Emtansine as Adjuvant Therapy for HER2-Positive Early Breast Cancer with Residual Invasive Disease in Colombia
{{output}}
Background: Patients with HER2-positive (HER2+) breast cancer (BC) who have residual invasive disease after neoadjuvant therapy remain at a significantly increased risk of recurrence. Updated results from the KATHERINE trial demo... ...
